Buy Reduxin online. Free worldwide shipping.
(aka Sibutramine, Meridia, Reduksin, Reductil)
Brand: PROMOMED RUS
Drug form: Hard gelatin capsules
Manufacturers: Ozone LLC. 445351, Russia, Samara region
Active substance: Sibutramine hydrochloride monohydrate
Group: Drugs for the treatment of obesity (excluding dietary products)
Expiration date: 3 years
More about the drug in Russian
We accept all the major cards including Visa, Maestro, Master Card and other. All the transactions are 100% secure and backed by Stripe financial services. Read more about the service.
We undertake all fees for the delivery and currency exchange.
Feel free to contact us in case of any questions: manager@befitpharma.com
REDUXIN (Sibutramine, Reductil, Meridia)
Indications for use of Reduxin are:
To reduce body weight in the following conditions:
alimentary obesity with a BMI of 30 kg / m2 or more;
alimentary obesity with a BMI of 27 kg / m2 or more in combination with type 2 diabetes mellitus and dyslipidemia.
Pharmachologic effect:
Pharmacological action - enterosorbent, anorexigenic.
Pharmacodynamics
Reduksin® is a combined preparation, the action of which is due to its constituent components.
Sibutramine is a prodrug and exerts its effect in vivo through metabolites (primary and secondary amines) that inhibit the reuptake of monoamines (serotonin, norepinephrine, and dopamine). An increase in the content of neurotransmitters in synapses increases the activity of central 5-HT-serotonin and adrenergic receptors, which contributes to an increase in the feeling of satiety and a decrease in the need for food, as well as an increase in thermal production. By indirectly activating beta3-adrenergic receptors, sibutramine acts on brown adipose tissue. The decrease in body weight is accompanied by an increase in the concentration of HDL in the blood plasma and a decrease in the amount of triglycerides, total cholesterol, LDL and uric acid. Sibutramine and its metabolites do not affect the release of monoamines, do not inhibit MAO; possess low affinity for a large number of neurotransmitter receptors, including serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2C), adrenergic (beta1-, beta2-, beta3-, alpha1-, alpha2-), dopamine (D1 , D2), muscarinic, histamine (H1), benzodiazepine and glutamate (NMDA) receptors.
MCC is an enterosorbent, has sorption properties and nonspecific detoxification effect. It binds and removes from the body various microorganisms, their metabolic products, toxins of exogenous and endogenous nature, allergens, xenobiotics, as well as an excess of certain metabolic products and metabolites responsible for the development of endogenous toxicosis.
Pharmacokinetics:
After oral administration, it is rapidly absorbed from the gastrointestinal tract by at least 77%. During the initial passage through the liver, it undergoes biotransformation under the influence of the isoenzyme CYP3A4 with the formation of two active metabolites - monodesmethylsibutramine (M1) and didesmethylsibutramine (M2). After taking a single dose of 15 mg Cmax in the blood plasma of M1 is 4 ng / ml (3.2-4.8 ng / ml), M2 - 6.4 ng / ml (5.6-7.2 ng / ml). Cmax is achieved after 1.2 hours (sibutramine), 3-4 hours (M1 and M2). Simultaneous food intake lowers the Cmax of metabolites by 30% and increases the time to reach it by 3 hours without changing the AUC. Distributes quickly to tissues. The protein bond is 97% (sibutramine) and 94% (M1 and M2). Css of active metabolites in blood plasma is reached within 4 days after the start of use and is approximately 2 times higher than the concentration in blood plasma after taking a single dose. T1 / 2 of sibutramine - 1.1 hours, M1 - 14 hours, M2 - 16 hours. Active metabolites undergo hydroxylation and conjugation to form inactive metabolites, which are excreted mainly by the kidneys.
Special patient groups
Floor. The limited data currently available do not indicate the existence of clinically significant differences in pharmacokinetics between men and women.
Elderly age. Pharmacokinetics in elderly healthy individuals (average age - 70 years) is similar to that in young people.
Renal failure Renal failure does not affect the AUC of active metabolites M1 and M2, except for the M2 metabolite in patients with end-stage renal failure on dialysis.
Liver failure. In patients with moderate hepatic impairment after a single dose of sibutramine, the AUC of active metabolites M1 and M2 is 24% higher than in healthy individuals.